News stories about Myovant Sciences (NASDAQ:MYOV) have been trending somewhat negative on Sunday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Myovant Sciences earned a news impact score of -0.11 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.7903558434925 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Myovant Sciences (NASDAQ MYOV) opened at 11.67 on Friday. The stock’s market cap is $703.47 million. Myovant Sciences has a 52 week low of $10.14 and a 52 week high of $15.50. The company has a 50-day moving average price of $11.47 and a 200-day moving average price of $11.82.
Separately, Zacks Investment Research cut Myovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $18.20.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.
